DrugPatentWatch Database Preview
Drugs in Development Information for Perifosine
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the drug development status for Perifosine?
Perifosine is an investigational drug.
There have been 43 clinical trials for Perifosine.
The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2009.
The most common disease conditions in clinical trials are Multiple Myeloma, Neoplasms, Plasma Cell, and Leukemia. The leading clinical trial sponsors are AEterna Zentaris, National Cancer Institute (NCI), and University of Wisconsin, Madison.
Summary for Perifosine
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 2,070 |
| WIPO Patent Applications | 1,546 |
| Japanese Patent Applications | 2 |
| Clinical Trial Progress | Phase 3 (2009-12-01) |
| Vendors | 84 |
Recent Clinical Trials for Perifosine
| Title | Sponsor | Phase |
|---|---|---|
| Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas | AEterna Zentaris | Phase 2 |
| Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas | Pfizer | Phase 2 |
| Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas | Andrew Lassman | Phase 2 |
Clinical Trial Summary for Perifosine
Top disease conditions for Perifosine
Top clinical trial sponsors for Perifosine
US Patents for Perifosine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
